HRS-7085 tablets

DRUG3 trials

Sponsors

Atridia Pty Ltd., Shandong Suncadia Medicine Co., Ltd., Jiangsu HengRui Medicine Co., Ltd.

Conditions

Inflammatory Bowel DiseaseModerate to Severe Ulcerative Colitis

Phase 1

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect.

CompletedNCT05638347

Atridia Pty Ltd.Inflammatory Bowel Disease

Start: 2022-12-05End: 2023-03-16Updated: 2023-04-21

A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of HRS-7085 Tablets in Healthy Subjects, With Assessment of Food Effects

Shandong Suncadia Medicine Co., Ltd.Inflammatory Bowel Disease

Start: 2023-12-31End: 2024-07-31Target: 70Updated: 2023-12-19

A Trial of HRS-7085 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis

Not yet recruitingNCT07760831

Jiangsu HengRui Medicine Co., Ltd.Moderate to Severe Ulcerative Colitis

Start: 2026-08-01End: 2027-09-01Target: 8Updated: 2026-08-12